These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12356752)

  • 1. Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 6-chloro-7-[corrected](2-morpholin-4-ylethylamino)-quinoline-5,8-dione.
    Pu L; Amoscato AA; Bier ME; Lazo JS
    J Biol Chem; 2002 Dec; 277(49):46877-85. PubMed ID: 12356752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
    Han Y; Shen H; Carr BI; Wipf P; Lazo JS; Pan SS
    J Pharmacol Exp Ther; 2004 Apr; 309(1):64-70. PubMed ID: 14718602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25.
    Lazo JS; Aslan DC; Southwick EC; Cooley KA; Ducruet AP; Joo B; Vogt A; Wipf P
    J Med Chem; 2001 Nov; 44(24):4042-9. PubMed ID: 11708908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at the G2/M transition.
    Timofeev O; Cizmecioglu O; Settele F; Kempf T; Hoffmann I
    J Biol Chem; 2010 May; 285(22):16978-90. PubMed ID: 20360007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. G2/M accumulation in prostate cancer cell line PC-3 is induced by Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2).
    Nemoto K
    Exp Ther Med; 2010 Jul; 1(4):647-650. PubMed ID: 22993588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors.
    Lazo JS; Nemoto K; Pestell KE; Cooley K; Southwick EC; Mitchell DA; Furey W; Gussio R; Zaharevitz DW; Joo B; Wipf P
    Mol Pharmacol; 2002 Apr; 61(4):720-8. PubMed ID: 11901209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual G1 and G2/M phase inhibition by SC-alpha alpha delta 9, a combinatorially derived Cdc25 phosphatase inhibitor.
    Tamura K; Rice RL; Wipf P; Lazo JS
    Oncogene; 1999 Nov; 18(50):6989-96. PubMed ID: 10597298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cdc25A-inhibitory properties and antineoplastic activity of bisperoxovanadium analogues.
    Scrivens PJ; Alaoui-Jamali MA; Giannini G; Wang T; Loignon M; Batist G; Sandor VA
    Mol Cancer Ther; 2003 Oct; 2(10):1053-9. PubMed ID: 14578470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase.
    Brisson M; Nguyen T; Vogt A; Yalowich J; Giorgianni A; Tobi D; Bahar I; Stephenson CR; Wipf P; Lazo JS
    Mol Pharmacol; 2004 Oct; 66(4):824-33. PubMed ID: 15231869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monensin-mediated growth inhibition in NCI-H929 myeloma cells via cell cycle arrest and apoptosis.
    Park WH; Kim ES; Kim BK; Lee YY
    Int J Oncol; 2003 Jul; 23(1):197-204. PubMed ID: 12792794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel cinnamic acid derivative that inhibits Cdc25 dual-specificity phosphatase activity.
    Aoyagi Y; Masuko N; Ohkubo S; Kitade M; Nagai K; Okazaki S; Wierzba K; Terada T; Sugimoto Y; Yamada Y
    Cancer Sci; 2005 Sep; 96(9):614-9. PubMed ID: 16128747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylations of cyclin-dependent kinase 2 revisited using two-dimensional gel electrophoresis.
    Coulonval K; Bockstaele L; Paternot S; Roger PP
    J Biol Chem; 2003 Dec; 278(52):52052-60. PubMed ID: 14551212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel synthetic inhibitor of CDC25 phosphatases: BN82002.
    Brezak MC; Quaranta M; Mondésert O; Galcera MO; Lavergne O; Alby F; Cazales M; Baldin V; Thurieau C; Harnett J; Lanco C; Kasprzyk PG; Prevost GP; Ducommun B
    Cancer Res; 2004 May; 64(9):3320-5. PubMed ID: 15126376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cdc25-dependent activation of cyclin A/cdk2 is blocked in G2 phase arrested cells independently of ATM/ATR.
    Goldstone S; Pavey S; Forrest A; Sinnamon J; Gabrielli B
    Oncogene; 2001 Feb; 20(8):921-32. PubMed ID: 11314027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand-based chemoinformatic discovery of a novel small molecule inhibitor targeting CDC25 dual specificity phosphatases and displaying in vitro efficacy against melanoma cells.
    Capasso A; Cerchia C; Di Giovanni C; Granato G; Albano F; Romano S; De Vendittis E; Ruocco MR; Lavecchia A
    Oncotarget; 2015 Nov; 6(37):40202-22. PubMed ID: 26474275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
    Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
    Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue.
    Tamura K; Southwick EC; Kerns J; Rosi K; Carr BI; Wilcox C; Lazo JS
    Cancer Res; 2000 Mar; 60(5):1317-25. PubMed ID: 10728693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells.
    Sandhu C; Donovan J; Bhattacharya N; Stampfer M; Worland P; Slingerland J
    Oncogene; 2000 Nov; 19(47):5314-23. PubMed ID: 11103932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of two growth inhibitory K vitamin analogs on cell cycle regulating proteins in human hepatoma cells.
    Markovits J; Wang Z; Carr BI; Sun TP; Mintz P; Le Bret M; Wu CW; Wu FY
    Life Sci; 2003 May; 72(24):2769-84. PubMed ID: 12679193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Methoxyestradiol inhibits hepatocellular carcinoma cell growth by inhibiting Cdc25 and inducing cell cycle arrest and apoptosis.
    Kar S; Wang M; Carr BI
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):831-40. PubMed ID: 18246350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.